TD Cowen Issues Positive Forecast for Incyte (NASDAQ:INCY) Stock Price

Incyte (NASDAQ:INCY) had its price target boosted by TD Cowen from $101.00 to $128.00 in a research note issued to investors on Tuesday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

Several other analysts also recently commented on the stock. The Goldman Sachs Group restated a “neutral” rating and set a $90.00 price objective on shares of Incyte in a research report on Thursday, January 8th. Zacks Research lowered Incyte from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 10th. JPMorgan Chase & Co. boosted their price objective on Incyte from $73.00 to $89.00 and gave the company a “neutral” rating in a research report on Thursday, October 9th. Royal Bank Of Canada increased their target price on Incyte from $81.00 to $84.00 and gave the stock a “sector perform” rating in a research report on Wednesday, October 29th. Finally, Oppenheimer cut Incyte from an “outperform” rating to a “market perform” rating in a report on Wednesday, October 8th. Ten investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $101.31.

Incyte Stock Performance

Shares of INCY opened at $103.43 on Tuesday. The business has a 50-day simple moving average of $102.21 and a two-hundred day simple moving average of $88.87. The company has a quick ratio of 3.13, a current ratio of 3.20 and a debt-to-equity ratio of 0.01. Incyte has a 52 week low of $53.56 and a 52 week high of $112.29. The stock has a market cap of $20.31 billion, a price-to-earnings ratio of 17.32, a PEG ratio of 0.64 and a beta of 0.82.

Incyte (NASDAQ:INCY) last announced its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $2.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.65 by $0.61. Incyte had a return on equity of 26.56% and a net margin of 24.69%.The company had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.26 billion. During the same period in the previous year, the company posted $1.07 EPS. The firm’s revenue was up 20.0% on a year-over-year basis. On average, analysts expect that Incyte will post 4.86 EPS for the current year.

Insider Buying and Selling at Incyte

In other news, EVP Steven H. Stein sold 20,105 shares of the stock in a transaction that occurred on Tuesday, December 2nd. The stock was sold at an average price of $102.51, for a total transaction of $2,060,963.55. Following the completion of the transaction, the executive vice president directly owned 63,129 shares in the company, valued at approximately $6,471,353.79. This represents a 24.15% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Sheila A. Denton sold 598 shares of the firm’s stock in a transaction on Tuesday, November 4th. The shares were sold at an average price of $101.36, for a total transaction of $60,613.28. Following the completion of the transaction, the executive vice president directly owned 26,569 shares of the company’s stock, valued at approximately $2,693,033.84. This trade represents a 2.20% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 98,897 shares of company stock worth $9,869,376. Company insiders own 17.80% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Arrowstreet Capital Limited Partnership increased its stake in Incyte by 701.8% during the second quarter. Arrowstreet Capital Limited Partnership now owns 2,730,648 shares of the biopharmaceutical company’s stock worth $185,957,000 after acquiring an additional 2,390,084 shares during the last quarter. AQR Capital Management LLC boosted its holdings in shares of Incyte by 21.8% in the 2nd quarter. AQR Capital Management LLC now owns 8,201,455 shares of the biopharmaceutical company’s stock worth $558,519,000 after purchasing an additional 1,465,286 shares during the period. Norges Bank bought a new position in shares of Incyte during the 2nd quarter valued at approximately $96,776,000. Pacer Advisors Inc. raised its holdings in Incyte by 8,091.6% during the 3rd quarter. Pacer Advisors Inc. now owns 1,248,642 shares of the biopharmaceutical company’s stock valued at $105,897,000 after buying an additional 1,233,399 shares during the period. Finally, Marshall Wace LLP bought a new stake in Incyte in the second quarter worth $82,485,000. Institutional investors own 96.97% of the company’s stock.

Key Stories Impacting Incyte

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: TD Cowen raised its price target from $101 to $128 and reiterated a Buy rating, implying meaningful upside and signaling confidence in Incyte’s pipeline and growth outlook. This upgrade likely supported buying interest earlier in the session. Benzinga
• Positive Sentiment: CEO Bill Meury emphasized that blood-cancer therapy development is central to Incyte’s identity and discussed potential M&A and product-pipeline execution on CNBC’s Fast Money — comments that investors typically view as constructive for longer-term revenue diversification and deal-led growth. Incyte CEO Bill Meury interview
• Neutral Sentiment: Pre-earnings commentary (Zacks, Barchart previews) highlights Incyte’s history of earnings beats and analysts projecting a double-digit surge in Q4 EPS — this raises expectations ahead of the report and increases the risk/reward around the release. Zacks beat article Barchart preview
• Neutral Sentiment: Incyte’s presentation at the J.P. Morgan Healthcare Conference and the published transcript keep the company in investors’ view — helpful for visibility but not an immediate catalyst unless new guidance or data were disclosed. J.P. Morgan transcript
• Neutral Sentiment: Marketing/brand activity (Winnie Harlow vitiligo campaign) may support commercial awareness for non-oncology assets but is unlikely to move the stock materially on its own. MMM Online
• Neutral Sentiment: Some analyst shops (Morgan Stanley) remain neutral/hold, reflecting balanced views that the stock has near-term strength but uncertainty beyond Jakafi — this maintains mixed pressure on the shares. TipRanks hold note
• Negative Sentiment: BMO Capital’s Evan Seigerman maintained a Sell rating and $75 price target, calling out a post-Jakafi revenue gap and execution risks — that contrasting negative view likely pressured the stock as investors weighed who’s right on long-term revenue sustainability. TipRanks BMO sell note

Incyte Company Profile

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.